OBIO 2018 Leadership Event Recap and Launch of ‘Use It or Lose It’ Report
On May 3, OBIO welcomed health science leaders, CEOs and the investment community to the tenth annual OBIO Leadership Event, also saw the launch of Use It or Lose It: Industry Solutions to Ontario's Commercialization Gap, OBIO's 2018 Industry Report.
OBIO Launches 'Use It or Lose It', Latest Report on the Future of Canada’s Health Science Industry
The Ontario Bioscience Innovation Organization (OBIO®) released its latest report, ‘Use It or Lose It: Industry Solutions to Ontario’s Commercialization Gap’, with recommendations from health science company executives on how to create the conditions for the growth of Ontario’s health science industry.
Proteocyte AI Announces Partnership With Proscia Digital
Proteocyte AI announced they have signed a partnership agreement to integrate Proscia’s technology with Straticyte™, a specific test for predicting the risk of progression to oral cancer.
OBIO CAAP Company Swift Medical Raises $11.6 Million in Oversubscribed Series A
Swift Medical, the world leader in enterprise-grade digital wound care management, has secured $11.6 million in funding
Register for Medical Device Playbook 2018, May 8th co-hosted by StarFish Medical and OBIO
Canada’s premiere innovation and commercialization event for medical device professionals, co-hosted by Starfish Medical and OBIO, Medical Device Playbook 2018 is coming to the MaRS Discovery District on May 8, 2018.
Applications Open for OBI ONtrepreneurs Program
Applications for the 2018 ONtrepreneurs Competition are now open. The Ontario Neurotech Entrepreneurs (ONtrepreneurs) Program catalyzes early stage entrepreneurs to commercialize brain-related technologies by accessing funding and support to launch or grow their neurotechnology ventures.
OBIO CAAP Company: Polumiros Wins 2018 FACIT Falcons' Fortunes competition
A panel of investor-judges has selected Ontario-based oncology researcher Soror Sharifpoor of Polumiros Inc. as the winner of the 2018 FACIT Falcons' Fortunes competition. The $50,000 award is intended to support further development of their innovative cancer research.
OBIO Pre-CAAP Company Adrenalease Launches KickStarter Campaign
Adrenalease announced the launch of a Kickstarter campaign to back their wearable posture apparel line. Once the campaign ends, the clothing is set to produce and ship to all backers by August 2018.
VBI Vaccines Announces Completion of Enrollment in PROTECT Phase 3 Clinical Study
VBI Vaccines announced the completion of enrollment with the last patient receiving the first dose in the ongoing PROTECT Phase 3 study of Sci-B-Vac®, the company’s third-generation hepatitis B vaccine.
OBIO CAAP Company CellAegis Announces First Patients Enrolled in U.S. SHIELD Pivotal Clinical Trial
CellAegis Devices announced enrollment of the first patients in a U.S. clinical trial of its autoRIC® device.
Impact Centre: Report on Physical Technologies Forum
The Impact Centre released a report on the Physical Technologies Forum, which summarized the ten big challenges Canada’s companies face when commercializing innovative physical technologies.
Ontario To Invest Up To $50M in Life Sciences Venture Capital Funds
Today, Ontario announced it will invest up to $50 million in venture capital funds focused on life sciences.
The Ontario Capital Growth Corporation (OCGC) has issued an expression of interest to identify fund managers to partner with other institutional investors such as corporations, banks and pension funds.
Avocare Launches Newest Product, Remote Care
Avocare has launched their newest product, Avocare Remote Care. Remote Care will empower patients by enabling them to securely message their own healthcare provider using secure web and mobile apps.
Federal Budget 2018 Analysis: Historic Investment in "Fundamental and Discovery Research"
Budget 2018 proposes an investment of nearly $4 billion in Canada’s research system. Robert Merson, Management Consultant, has prepared an analysis of this year's Budget 2018, focusing on research and innovation investment.
Hamilton Health Sciences & IBM Innovation Exchange: Upcoming Call for Proposals
Hamilton Health Sciences & IBM's innovation exchange provides innovators – research scientists, industry & academic partners, start-ups and scale-ups – with technologies they otherwise would not have access to, to advance the pursuit of solutions to challenges in healthcare.
New Funding Opportunites: Weston Brain Institute
The Weston Brain Institute is launching three new funding programs:
Rapid Response: Canada 2018 (Alzheimer’s and Related Diseases)
International Fellowships: Canada 2018
International Outstanding Achievement Award 2018
Nanovista Receives $1.8M Investment to Develop Advanced Imaging Agents
Nanovista Inc., a start-up company co-founded by Drs. David Jaffray, Jinzi Zheng, and Christine Allen of UHN and the University of Toronto, recently received investments of $1.8M with the help of GreenSky Capital Inc. and its affiliated venture capital funds.
Nanovista also recently welcomed Steven Chackowicz as its new CEO. A serial entrepreneur, he has experience in leadership roles in companies that include Exact Imaging, Aspect Imaging and VisualSonics.
Showcasing Ontario's High Potential Companies: Niagara Emerging Health Sciences Company Forum - Part 2
This week, in Part 2 of a blog that began last week, we review the Niagara Emerging Health Science Company Forum, held in Niagara-on-the-Lake on Feb 1-2, 2018.
The forum brought together CEOs and senior executives from high potential Canadian health science companies with senior leadership from American investors and strategics in beautiful Niagara-on-the-Lake for two days of panel presentations, executive roundtables, and networking dinners.
OBIO Requests Immediate Input: Ontario Health Science Technology Pipeline
OBIO is working to develop a model that will advance early access to the Ontario market. Critical to the development of this initiative is the ability to quantify the Ontario health science technology pipeline by category and stage of readiness to address the barriers to market access.
UHN Startup AVROBIO Inc. Announces $60 Million Series B Financing
AVROBIO, Inc., a clinical-stage biotechnology company developing transformative, life-changing gene therapies for rare diseases, announced today that it has completed a $60 million Series B financing.